Cubist Systematic Strategies
LYEL icon

Cubist Systematic Strategies’s Lyell Immunopharma LYEL Stock Holding History

Cubist Systematic Strategies’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,438
Closed -$64.1K – 3579
2024
Q1 		$64.1K Sell
1,438
-1,645
-53% -$70.4K ﹤0.01% 3341
2023
Q4 		$120K Buy
+3,083
New +$111K ﹤0.01% 3142
2023
Q2 		– Sell
-2,473
Closed -$117K – 3971
2023
Q1 		$117K Buy
+2,473
New +$132K ﹤0.01% 3410
2022
Q4 		– Sell
-1,506
Closed -$221K – 4440
2022
Q3 		$221K Buy
+1,506
New +$204K ﹤0.01% 3699
2022
Q2 		– Sell
-2,440
Closed -$246K – 4462
2022
Q1 		$246K Sell
2,440
-5,854
-71% -$709K ﹤0.01% 2950
2021
Q4 		$1.28M Buy
8,294
+6,261
+308% +$1.4M 0.01% 1727
2021
Q3 		$602K Buy
2,033
+1,743
+601% +$522K 0.01% 1901
2021
Q2 		$94K Buy
+290
New +$95.1K ﹤0.01% 2718

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WA
WuXi AppTec Shanghai, China $19M AUM 20.22% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cubist Systematic Strategies's LYEL Position: Q2 2024 in Review

Cubist Systematic Strategies sold out of Lyell Immunopharma (LYEL) in Q2 2024, closing a stake of 1,438 shares — an estimated $64.1K sold.

Cubist Systematic Strategies first reported a position in LYEL in Q2 2021 and held it in 8 quarters. The position peaked at $1.28M in Q4 2021. 120 funds tracked by Wall St. Rank hold LYEL as of Q2 2024.

  • Cubist Systematic Strategies reported no remaining Lyell Immunopharma position as of Q2 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 1,438 Lyell Immunopharma shares in Q2 2024, an estimated $64.1K.
  • Cubist Systematic Strategies first reported a position in Lyell Immunopharma in Q2 2021 and held it in 8 quarters.
  • Cubist Systematic Strategies's Lyell Immunopharma position peaked at $1.28M in Q4 2021.
  • 120 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2024.

Based on Cubist Systematic Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.